Methods for producing and using S-nitrosohemoglobins

Details Methods for producing and using S-nitrosohemoglobins Methods for producing and using S-nitrosohemoglobins

2005-02-15

2005-02-15

Celsa, Bennett (Department: 1639)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S002600, C514S832000, C530S385000, C530S829000, C604S028000

Reexamination Certificate

active

06855691

ABSTRACT:
Nitric oxide (NO) interacts with hemoglobin (Hb) at its metal centers, whereas S-nitrosothiols (RSNOs) can donate the NO group to β93 cysteine residues, thereby shielding the NO functionality from heme inactivation. S-nitrosylation of Hb is under the allosteric control of oxygen and the oxidation state of heme. NO group release from S-nitrosohemoglobin (SNO-Hb) is further facilitated by intracellular low molecular weight thiols, forming RSNOs which can be exported from the erythrocyte to regulate blood pressure. Hence, a dynamic cycle is established in which S-nitrosylation of Hb is initiated in the lung following oxygenation of red blood cells and is completed by SNO-Hb metabolism during arterial-venous transit. SNO-Hb can be formed by reaction of Hb with S-nitrosothiol. This procedure avoids oxidation of the heme. SNO-Hb in its various forms and combinations thereof (oxy, deoxy, met; S-nitrosylated to various extents) can be administered to a mammal in a method of therapy where it is desired to oxygenate, to scavenge free radicals, or to release NO groups to tissues. Thiols can also be administered to enhance the transfer of NO groups. Examples of conditions to be treated by SNO-Hb therapy include ischaemic injury, hypertension, angina, reperfusion injury and inflammations.

REFERENCES:
patent: 4900719 (1990-02-01), Means et al.
patent: 5152979 (1992-10-01), Hunter
patent: 5380758 (1995-01-01), Stamler et al.
patent: 5395314 (1995-03-01), Klatz et al.
patent: 5405919 (1995-04-01), Keefer et al.
patent: 5427797 (1995-06-01), Frostell et al.
patent: 5439882 (1995-08-01), Feola et al.
patent: 5480866 (1996-01-01), Bonaventura et al.
patent: 5574068 (1996-11-01), Stamler et al.
patent: 5593876 (1997-01-01), Stamler et al.
patent: 5863890 (1999-01-01), Stamler et al.
patent: 6087479 (2000-07-01), Stamler et al.
patent: 6255277 (2001-07-01), Stamler et al.
patent: 6291424 (2001-09-01), Stamler et al.
patent: 6583113 (2003-06-01), Stamler et al.
patent: 20020052314 (2002-05-01), Stamler et al.
patent: 20030007967 (2003-01-01), Stamler et al.
patent: 20030022267 (2003-01-01), Stamler et al.
patent: WO 9309806 (1993-05-01), None
patent: WO 9312068 (1993-06-01), None
patent: WO 9422306 (1994-10-01), None
patent: WO 9422482 (1994-10-01), None
patent: WO 9422499 (1994-10-01), None
patent: WO 9507691 (1995-03-01), None
patent: WO 9603139 (1996-02-01), None
patent: WO 9615797 (1996-05-01), None
patent: WO 9616645 (1996-06-01), None
patent: WO 9617604 (1996-06-01), None
patent: WO 9630006 (1996-10-01), None
patent: WO 9718000 (1997-05-01), None
60/003,801 (currently unavailable to the Examiner).*
U.S. Appl. No. 08/123,331, filed Sep. 17, 1993, now abandoned.
U.S. Appl. No. 08/438,418, filed May 10, 1995, now U.S. 6,255,277.
U.S. Appl. No. 08/460,465, filed Jun. 2, 1995, now U.S. 6,087,479.
U.S. Appl. No. 09/433,550, filed Nov. 4, 1999, now U.S. 6,174,539.
U.S. Appl. No. 09/621,610, filed Jul. 21, 2000, now U.S. 6,471,978.
U.S. Appl. No. 09/661,190, filed Sep. 13, 2000, now U.S. 6,352,709.
U.S. Appl. No. 07/791/668, filed Nov. 14, 1991, now abandoned.
U.S. Appl. No. 07/943,835, filed Sep. 14, 1992, now abandoned.
U.S. Appl. No. 08/198,854, filed Feb. 17, 1994, now abandoned.
U.S. Appl. No. 08/287,830, filed Aug. 9, 1994, now U.S. 5,593,876.
U.S. Appl. No. 08/437,868, filed May 9, 1995, now abandoned.
U.S. Appl. No. 08/907,217, filed Aug. 6, 1997, now U.S. 5,863,890.
U.S. Appl. No. 09/092,622, filed Jun. 5, 1998, now U.S. 6,291,424.
U.S. Appl. No. 09/835,038, filed Apr. 16, 2001, published as 20020052314 (cited on PTO form 1449). The status and currently pending claims on this application are not known to Applicant.
U.S. Appl. No. 10/216,865, filed Aug. 13, 2002, published as 20030007967 (cited on PTO form 1449). The status and currently pending claims of this application are not known to Applicant.
U.S. Appl. No. 08/281,427, filed Jul. 27, 1994, which is the priority application for WO 96/03139. Status unknown to Applicant.
U.S. Appl. No. 08/043,653, filed Apr. 6, 1993, now U.S. 5,427,797.
U.S. Appl. No. 10/066,320, filed Jan. 31, 2002, published as 20030022267 (cited on PTO form 1449). A copy of the claims currently pending is attached.
U.S. Appl. No. 10/280,085, filed Oct. 25, 2002. A copy of the claims currently pending is attached.
Search results from Derwent Work Patent Index: Stamler patent applications as of Mar. 12, 2001 (26 pages).
Stamler, Jonathan S. et al., “S-Nitrosylation of Proteins with Nitric Oxide: Synthesis and Characterization of Biologically Active Compounds,”Proc. Natl. Acad Sci. USA, 89:444-448 (1992).
Langford, E.J. et al., “Inhibition of Platelet Activity by S-Nitrosoglutathione During Coronary Angioplasty,”The Lancet, 344:1458-1460 (1994).
Ribeiro, JoséM.C. et al., “Reversible Binding of Nitric Oxide by a Salivary Heme Protein from a Bloodsucking Insect,”Science, 260:539-541 (1993).
Simon, Daniel I. et al., “Effect of Nitric Oxide Synthase Inhibition on Bleeding Time in Humans,”Journal of Cardiovascular Pharmacology, 26:339-342 (1995).
Olsen, Stephen B. et al., “Enhancement of Platelet Deposition by Cross-Linked Hemoglobin in a Rat Carotid Endarterectomy Model,”Circulation, 93(2):327-332 (1996).
Scharfstein, Jonathan S. et al., “In Vivo Transfer of Nitric Oxide Between a Plasma Protein-Bound Reservoir and Low Molecular Weight Thiols,”J. Clin. Invest., 94:1432-1439 (1994).
Stamler, Jonathan S., “Redox Signaling: Nitrosylation and Related Target Interactions of Nitric Oxide,”Cell, 78:931-936 (1994).
Arnelle, Derrick R. and Stamler, Jonathan S., “NO+, NO·, and NO−Donation by S-Nitrosothiols: Implications for Regulation of Physiological Functions by S-Nitrosylation and Acceleration of Disulfide Formation,”Archives of Biochemistry and Biophysics, 318(2):279-285 (1995).
Kondo, T. et al., “Thiol Transport from Human Red Blood Cells,”Methods in Enzymology, 252:72-82 (1995).
Wheeler, G.P. et al., “Anti-Sickling Activity of Nitrosoureas,”Biochem. Biophys. Res. Comm. 54(3):1024-1029 (1973).
Kosaka, H. et al., “ESR Spectral Transition by Arteriovenous Cycle in Nitric Oxide Hemoglobin of Cytokine-Treated Rats,”Am. J. Physiol., 266(5):1400-1405 (1994).
Kruszyna, R. et al., “Generation of Valency Hybrids and Nitrosylated Species of Hemoglobin in Mice by Nitric Oxide Vasodilators,”Toxicol. Appl. Pharmacol., 94(3):458-465 (1988).
Doyle, Michael P. et al., “Structural Effects in Alkyl Nitrite Oxidation of Human Hemoglobin,”Journal of Biological Chemistry. 259(1):80-87 (1984).
Shah, N.S. et al., “Efficiacy of Inhaled Nitric Oxide in a Porcine Model of Adult Respiratory Distress Syndrome,”Archives of Surgery, 129(2):158-164 (1994).
Kukovetz, W.R. et al., “Cellular Mechanism of Action of Therapeutic Nitric Oxide Donors,”European Heart Journal, 12 (Suppl. E):16-24 (1991).
Greenburg, A.G and Kim, H.W., “Nitrosyl Hemoglobin Formation In Vivo After Intravenous Administration of a Hemoglobin-Based Oxygen Carrier in Endotoxemic Rats,”Artif. Cells, Blood Substitutes, Immobilization Biotechnol., 23(3):271-276 (1995).
Clancy, Robert M. et al., “Use of Thionitrobenzoic Acid to Characterize the Stability of Nitric Oxide in Aqueous Solutions and in Porcine Aortic Endothelial Cell Suspensions,”Anal. Biochem., 191(1):138-143 (1990).
Charache, S. et al., “Evaluation of Extracorporeal Alkylation of Red Cells as a Potential Treatment for Sickle Cell Anemia,”Blood, 47(3):481-488 (1976).
Feelisch, M. and Stamler, J.S., “Donors of Nitrogen Oxides,”Methods In Nitric Oxide Research, John Wiley & Sons Ltd. (1996).
Stamler, J.S. and Feelisch, M., “Preparation and Detection of S-Nitrosothiols,”Methods in Nitric Oxide Research, John Wiley & Sons Ltd. (1996).
Clancy, Robert M. al., “Nitric Oxide Reacts with Intracellular Glutathione and Activates the Hexose Monophosphate Shunt in Human Neutrophils:

Affiliated with

Also associated with

Rating

Methods for producing and using S-nitrosohemoglobins does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for producing and using S-nitrosohemoglobins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for producing and using S-nitrosohemoglobins will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3480504